Annals of Hematology

, Volume 91, Issue 10, pp 1613–1622

Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines

  • Maria Cosenza
  • Monica Civallero
  • Giulia Grisendi
  • Luigi Marcheselli
  • Erika Roat
  • Alessia Bari
  • Stefano Sacchi
Original Article

DOI: 10.1007/s00277-012-1490-6

Cite this article as:
Cosenza, M., Civallero, M., Grisendi, G. et al. Ann Hematol (2012) 91: 1613. doi:10.1007/s00277-012-1490-6

Abstract

Less toxic and more active treatments are needed for indolent lymphomas as there is no curative treatment, and patients eventually die due to complications related to their disease. The purpose of the present study was to assess the antitumour activity of the combination of low doses of Enzastaurin and Lenalidomide (Revlimid) on B-lymphoma cell lines. The combination of Enzastaurin and Lenalidomide, at doses as low as 1 μM, showed strong synergism against indolent lymphomas by reducing cell growth, producing an increase in G0–G1 phase followed by significant decrease in S phase, increasing apoptosis, and inhibiting PI3K/AKT, PKC and MAPK/ERK pathways. These preclinical findings, together with promising results obtained with Lenalidomide for the treatment of non-Hodgkin lymphoma, suggest that further evaluation of the combination of Enzastaurin and Lenalidomide for the treatment of indolent lymphomas is warranted. These compounds, with a favourable toxicity profile, are not classic chemotherapeutic agents, causing severe side effects, and could be considered an example of a new innovative attempt of an anti-cancer ‘soft treatment’.

Keywords

Indolent B-cell lymphoma Enzastaurin Lenalidomide Signaling pathways AKT MAPK 

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Maria Cosenza
    • 1
  • Monica Civallero
    • 1
  • Giulia Grisendi
    • 1
  • Luigi Marcheselli
    • 1
  • Erika Roat
    • 2
  • Alessia Bari
    • 1
  • Stefano Sacchi
    • 1
  1. 1.Program of Innovative Therapies in Oncology and Haematology, Department of Oncology and HematologyUniversity of Modena and Reggio EmiliaModenaItaly
  2. 2.Department of Biomedical SciencesUniversity of Modena and Reggio EmiliaModenaItaly

Personalised recommendations